Rodman & Renshaw analyst Elemer Piros adjusted the firm’s price target on Clene to $97 from $5 and keeps a Buy rating on the shares due to the recently announced 1:20 reverse split. The firm says that while it is difficult to handicap an FDA opinion, the depth and breadth of the data package presented by Clene bodes well for potential accelerated approval of CNM-Au8 with a post-approval commitment to corroborate earlier findings.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Clene to Present at the Emerging Growth Conference
- Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
- Clene announces plans to submit briefing book to U.S. FDA
- Clene trading halted, news pending
- Clene Announces Reverse Stock Split and Share Structure Changes